Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Guy Peachey"'
Autor:
Dawn Edwards, Edward Kerwin, Louis-Philippe Boulet, Guy Brusselle, Ian D. Pavord, Huib A. M. Kerstjens, Maggie Tabberer, Neal Sule, Robert A. Nathan, Nicola A. Hanania, Neil Barnes, John Oppenheimer, Guy Peachey, Steven Pascoe, Zelie Bailes, Andrew Fowler, Laurie A Lee, Alberto Papi
Publikováno v:
The Lancet. Respiratory Medicine, 9(1), 69-84. ELSEVIER SCI LTD
Background:Despite inhaled corticosteroid plus long-acting β2-agonist (ICS/LABA) therapy, 30–50% of patients with moderate or severe asthma remain inadequately controlled. We investigated the safety and efficacy of single-inhaler fluticasone furoa
Autor:
Laurie Lee, Michael E. Manning, Neal Sule, Maggie Tabberer, Ian D. Pavord, David M. Mannino, Andrew Fowler, John Oppenheimer, Nicola A. Hanania, Mark Millard, Robert A. Nathan, Guy Peachey, Edward Kerwin, Huib A. M. Kerstjens, Agne Zarankaite
Publikováno v:
Chest. 158:A35-A38
Autor:
Steven Weinstein, Agne Zarankaite, Robert A. Nathan, Edward Kerwin, Louis-Philippe Boulet, Alberto Papi, Neal Sule, Andrew Fowler, David M. Mannino, Mark C. Liu, Diego Maselli Caceres, Ian D. Pavord, Nicola A. Hanania, John Oppenheimer, Guy Peachey, Laurie Lee, Huib A. M. Kerstjens
Publikováno v:
Chest. 158:A2621-A2625
Publikováno v:
Clinical pharmacokinetics. 60(7)
This analysis aimed to characterize the pharmacokinetics (PK) of the inhaled corticosteroid (ICS) fluticasone furoate (FF), the long-acting muscarinic antagonist umeclidinium (UMEC), and the long-acting β2-agonist (LABA) vilanterol (VI), administere
Autor:
Neil Barnes, Guy Peachey, Huib A. M. Kerstjens, Ian D. Pavord, Andrew Fowler, John Oppenheimer, Agne Zarankaite, Neal Sule, Nicola A. Hanania, Emilio Pizzichini, Steven Pascoe, Laurie Lee, Edward Kerwin, Robert A. Nathan, Louis-Philippe Boulet
Publikováno v:
Airway pharmacology and treatment.
Background: CAPTAIN assessed moderate (mod.) and severe (sev.) exacerbations in patients with inadequately controlled asthma randomised to ICS-based dual/triple therapy for 24–52 wks. Aim: Assess changes in lung function (LF)/clinical characteristi
Autor:
Edward Kerwin, Dawn Edwards, Huib A. M. Kerstjens, Steven Pascoe, Laurie Lee, Zelie Bailes, Guy Peachey, Ian D. Pavord, Andrew Fowler, Maggie Tabberer, L.-P. Boulet, John Oppenheimer, Alberto Papi, Robert A. Nathan, Neil Barnes, Nicola A. Hanania
Publikováno v:
B93. LATE BREAKING CLINICAL TRIALS IN AIRWAY DISEASES.
Autor:
John Oppenheimer, Neil Barnes, Huib A. M. Kerstjens, Maggie Tabberer, Laurie Lee, Z. Bailes, A. Fowler, Guy Peachey
Publikováno v:
C61. ASTHMA: CLINICAL STUDIES.
Autor:
Maggie Tabberer, Huib A. M. Kerstjens, Steven Pascoe, Louis-Philippe Boulet, Zelie Bailes, Neal Sule, Dawn Edwards, Guy Peachey, Laurie Lee, Neil Barnes, Ian D. Pavord, Andrew Fowler, Robert A. Nathan, Edward Kerwin, Nicola A. Hanania
Publikováno v:
Journal of Allergy and Clinical Immunology. 145:AB241
Autor:
Frances Gardiner, Dawn Edwards, Huib A. M. Kerstjens, Neal Sule, Laurie Lee, Edward Kerwin, Nicola A. Hanania, Neil Barnes, Guy Peachey, Steven Pascoe, Zelie Bailes, Ian D. Pavord, Andrew Fowler
Publikováno v:
Journal of Allergy and Clinical Immunology. 145:AB24
Autor:
J. Bruce, Guy Peachey, Panayiotis Georgiou, Chien-Wei Chen, Gert-Jan Braunstahl, Robert Maykut
Publikováno v:
Respiratory Medicine. 107:1141-1151
Summary Omalizumab has demonstrated therapeutic benefits in controlled clinical trials. Evaluation of outcomes in real-world clinical practice is needed to provide a complete understanding of the benefits of omalizumab treatment. eXpeRience was a 2-y